Any current/future new fundraising through debt or equity?

The transcript does not explicitly mention any current or planned new fundraising through debt or equity. Rajesh Rathi and other management highlighted focus on reducing net debt by liquidating inventory of EUR 30-40 million, which should improve balance sheet and reduce working capital. Interest cost on borrowings is currently around 5.75% to 6% (excluding IndAS lease accounting costs). No specific mention of any equity issuance or debt refinancing plans. Management is focused on cost optimization, working capital improvements, and operational efficiencies to improve financial metrics rather

Any current/future capex/capital investment/strategic investment?

Sudarshan Chemical Industries is focusing on cost reduction and value capture initiatives across operations, procurement, organization, IT, and fixed costs, aiming for EUR 90-100 million EBITDA in 3-4 years. The company has inaugurated a Global Capability Center (GCC) on February 4, 2026, aiming to ramp up operations over the next year and improve productivity and response time via digital innovation. There is a major initiative to harmonize multiple SAP systems into one by December 2026, enhancing efficiency by simplifying invoicing and process integration. Manufacturing footprint rationaliza

Future growth expectations in sales/revenue/volumes?

Legacy Sudarshan business: Expected to return to its long-term growth rate of around 10-11% CAGR, with growth resuming from Q4 FY '26 onwards. Acquired business (Heubach): Anticipated sales growth after inventory destocking phase; production volumes will initially lag sales, normalizing post-Q2 FY '27. Demand Improvement: Customers showed subdued demand in first 7-8 months but demand improved substantially after November, indicating recovery. New product investments in legacy business are performing well, with growing demand and potential margin improvements. Overall revenue growth is

Future growth expectations in earnings/operating earnings/profits/EPS?

Legacy Sudarshan business is expected to return to a long-term sustainable growth rate of around 10%-11% CAGR (Rajesh Rathi, Page 13). The company anticipates gradual improvement in operating performance with cost optimization and working capital initiatives, resulting in building up to ~10% margin or close to EUR 90-100 million EBITDA over the next few years (Page 14). Synergies and cost savings pipeline is strong, with a 3-4 year target to deliver EUR 90-100 million EBITDA largely through cost reduction and normalized sales (Page 9). The impact of inventory reduction (EUR 30-40 million reduc

Current/ Expected Orderbook/ Pending Orders?

Management expressed confidence in demand improvement starting January and early February, indicating a positive trend in order inflow. Customers had promised to start buying after January, reflecting an uptick in orderbook. The subdued demand in prior quarters was mainly due to customer destocking rather than weak end-market orders. There is no explicit mention of a large existing order backlog or pending orders; confidence seems based on renewed customer buying behavior and market recovery. The company expects demand normalization, supported by customer trust and improved supply chain proces

IN US

Sale is live|00:00:00left today

Sudarshan Chemical Industries LtdQ4 FY27Chemicals & Petrochemicals

Sudarshan Chemical Industries Ltd Q4 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹891P/E: 1959.9Market Cap: ₹7.2K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 4

Margin

Category 2

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 4

→Legacy Sudarshan business: Expected to return to its long-term growth rate of around 10-11% CAGR, with growth resuming from Q4 FY '26 onwards.
→Acquired business (Heubach): Anticipated sales growth after inventory destocking phase; production volumes will initially lag sales, normalizing post-Q2 FY '27.
→Demand Improvement: Customers showed subdued demand in first 7-8 months but demand improved substantially after November, indicating recovery.
→New product investments in legacy business are performing well, with growing demand and potential margin improvements.
→Overall revenue growth is expected to be gradual and back-ended with a ramp-up as cost optimization and synergies take effect.
→Industry-wide demand challenges are seen as temporary; normal buying patterns expected to resume, supporting volume growth.

Margin guidance

Category 2

→Legacy Sudarshan business is expected to return to a long-term sustainable growth rate of around 10%-11% CAGR (Rajesh Rathi, Page 13).
→The company anticipates gradual improvement in operating performance with cost optimization and working capital initiatives, resulting in building up to ~10% margin or close to EUR 90-100 million EBITDA over the next few years (Page 14).
→Synergies and cost savings pipeline is strong, with a 3-4 year target to deliver EUR 90-100 million EBITDA largely through cost reduction and normalized sales (Page 9).
→The impact of inventory reduction (EUR 30-40 million reduction) will positively affect cash flow and net debt but may temporarily suppress reported EBITDA by EUR 9-12 million over the next 3 quarters, normalizing thereafter (Page 6-7).
→Confident of improved profitability from Q4 FY26 onwards supported by customer restocking and demand recovery (Page 14).
→EPS was negative INR 1.4 in the reported period but outlook is positive with margin expansion and demand normalization (Page 6).

3 more insights locked — sign up free to unlock

Fundraise plans

→The transcript does not explicitly mention any current or planned new fundraising through debt or equity.
→Rajesh Rathi and other management highlighted focus on reducing net debt by liquidating inventory of EUR 30-40 million, which should improve balance sheet and reduce working capital.
→Interest cost on borrowings is currently around 5.75% to 6% (excluding IndAS lease accounting costs).
→No specific mention of any equity issuance or debt refinancing plans.
→Management is focused on cost optimization, working capital improvements, and operational efficiencies to improve financial metrics rather than relying on new capital raising at this point.

Order book

→Management expressed confidence in demand improvement starting January and early February, indicating a positive trend in order inflow.
→Customers had promised to start buying after January, reflecting an uptick in orderbook.
→The subdued demand in prior quarters was mainly due to customer destocking rather than weak end-market orders.
→There is no explicit mention of a large existing order backlog or pending orders; confidence seems based on renewed customer buying behavior and market recovery.
→The company expects demand normalization, supported by customer trust and improved supply chain processes.
→Overall, orderbook visibility appears positive for Q4 FY26 and beyond, driven by genuine demand recovery rather than one-time restocking.

Capex plans

Yes

→Sudarshan Chemical Industries is focusing on cost reduction and value capture initiatives across operations, procurement, organization, IT, and fixed costs, aiming for EUR 90-100 million EBITDA in 3-4 years.
→The company has inaugurated a Global Capability Center (GCC) on February 4, 2026, aiming to ramp up operations over the next year and improve productivity and response time via digital innovation.
→There is a major initiative to harmonize multiple SAP systems into one by December 2026, enhancing efficiency by simplifying invoicing and process integration.
→Manufacturing footprint rationalization has been largely completed, such as rightsizing Frankfurt operations and transferring production to India; no further major manufacturing changes planned.
→Inventory liquidation is underway to reduce working capital and net debt, with expected positive balance sheet impact but short-term P&L impact due to overhead absorption.
→No explicit mention of new capital expenditure on production capacity expansion, focusing more on operational optimization and integration.

How does Sudarshan Chemical Industries Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Sudarshan Chemical Industries Ltd

Rev 4Mar 2

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Sudarshan Chemical Industries Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio